請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/93223
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡凱焜 | zh_TW |
dc.contributor.advisor | Kae-Kuen Hu | en |
dc.contributor.author | 廖顯達 | zh_TW |
dc.contributor.author | Hsien-Ta Liao | en |
dc.date.accessioned | 2024-07-23T16:22:26Z | - |
dc.date.available | 2024-07-24 | - |
dc.date.copyright | 2024-07-23 | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-07-15 | - |
dc.identifier.citation | Alosert, H., Savery, J., Rheaume, J., Cheeks, M., Turner, R., Spencer, C., S. Farid, S., & Goldrick, S. (2022). Data integrity within the biopharmaceutical sector in the era of Industry 4.0. Biotechnology Journal, 17(6), 2100609.
Ambrosini, V., & Bowman, C. (2009). What are dynamic capabilities and are they a useful construct in strategic management? International journal of management reviews, 11(1), 29-49. Anttonen, E., Harmik, B., Dubs, M., Helliwell, I., & Selva, J. (2017). Digital Plant Maturity Model (DPMM) V1: The Development of a Digital Plant Maturity Model to Aid Transformation in Biopharmaceutical Manufacturing. BioPhorum, February, 17. Arden, N. S., Fisher, A. C., Tyner, K., Yu, L. X., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. Int J Pharm, 602, 120554. https://doi.org/10.1016/j.ijpharm.2021.120554 Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of management, 17(1), 99-120. BMI. (2023). Taiwan, China Pharmaceuticals Report Includes 10-year forecasts to 2032. . Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. Administrative science quarterly, 35(1), 128-152. Ding, B. (2018). Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. Process Safety and Environmental Protection, 119, 115-130. https://doi.org/https://doi.org/10.1016/j.psep.2018.06.031 Eisenhardt, K. M., & Martin, J. A. (2000). Dynamic capabilities: what are they? Strategic management journal, 21(10‐11), 1105-1121. Gemmell, D. (2022). The Future of Biopharma. Grant, R. M. (1991). The resource-based theory of competitive advantage: implications for strategy formulation. California management review, 33(3), 114-135. Group, B. O. (2017). Biomanufacturing technology roadmap: Executive summary. Heinonen, S. (2022). Analyzing understanding and role of sustainability in the pharmaceutical industry. ISPE. (December 2023). Baseline Guide Vol 8: Pharma 4.0 1st Edition. Jeong, H., Song, C., Kim, S., & Shin, K. (2023). Quantum jump in biopharmaceutical industry: a case of Korea’s catching up with Europe and US. European Planning Studies, 31(5), 885-904. Kumar, S. H., Talasila, D., Gowrav, M., & Gangadharappa, H. (2020). Adaptations of Pharma 4.0 from Industry 4.0. Drug Invention Today, 14(3). Macdonald, G. J. (2022). Going Digital Can Help CDMOs Upgrade Their Value Propositions. Mathews, J. A. (2002). Competitive advantages of the latecomer firm: A resource-based account of industrial catch-up strategies. Asia Pacific journal of management, 19, 467-488. Neumann, J. (2022). 2022全球生技醫藥CDMO趨勢. Saaty, T. L. (1980). The analytic hierarchy process (AHP). The Journal of the Operational Research Society, 41(11), 1073-1076. SamsungBiologics. (2020). Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience. Contract Pharma. Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery, 11(3), 191-200. Sharma, D., Patel, P., & Shah, M. (2023). A comprehensive study on Industry 4.0 in the pharmaceutical industry for sustainable development. Environmental Science and Pollution Research, 30, 1-11. https://doi.org/10.1007/s11356-023-26856-y Silva, F., Resende, D., Amorim, M., & Borges, M. (2020). A Field Study on the Impacts of Implementing Concepts and Elements of Industry 4.0 in the Biopharmaceutical Sector. Journal of Open Innovation: Technology, Market, and Complexity, 6(4). https://doi.org/10.3390/joitmc6040175 Teece, D. J., Pisano, G., & Shuen, A. (1997). Dynamic capabilities and strategic management. Strategic management journal, 18(7), 509-533. Wang, C. L., & Ahmed, P. K. (2007). Dynamic capabilities: A review and research agenda. International journal of management reviews, 9(1), 31-51. Weiss, L., & Hobson, J. M. (1995). States and economic development: a comparative historical analysis. (No Title). 王振寰. (2010). 追趕的極限: 臺灣的經濟轉型與創新 (Vol. 1). 巨流圖書股份有限公司. 李爾芳. (2022). 智慧製造科技於生物製藥產業之應用. 許文靜. (2017). 台灣製藥廠商的成長驅動因素: 技術後進者的觀點. 清華大學科技管理研究所學位論文, 2017, 1-74. 郭孟勳. (2023). 台灣製藥委託開發暨製造服務公司(CDMO)之發展策略研究 國立清華大學]. 臺灣博碩士論文知識加值系統. 陳建榮. (2021). 生物製劑製造代工 市場與成長契機. 陳琮淵, & 王振寰. (2009). 臺灣的生技製藥產業: 發展, 創新與限制. 曾維薇. (2024). 2024年生技醫療產業發展趨勢. 台灣經濟研究月開. 資誠全球聯盟組織. (2022). 2022全球生技醫藥CDMO趨勢. 蔡淑娟. (2022). 台灣CDMO製藥公司之商業模式分析 蔡維原. (2021). 2021年第一季我國製藥產業回顧與展望. 鄧振源, & 曾國雄. (1989). 分析層級法的內涵特性與應用 (上). 中國統計學報. 鄭宇婷. (2021). 全球生物藥品CDMO發展概況. 瞿宛文. (2000). 全球化與後進國之經濟發展. 台灣社會研究季刊(37), 91-117. 瞿宛文. (2015). 产业升级之路——以中国台湾地区为例. 世界经济文汇, 01(特刊), 71-84. http://sjjjwh.magtech.com.cn/CN/abstract/article_504.shtml | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/93223 | - |
dc.description.abstract | 本研究旨在分析台灣生物製藥CDMO(Contract Development and Manufacturing Organization)產業的現況與未來發展,並構建一個名為BAMBOO的模型,以比喻台灣生物製藥產業的特性與發展策略。BAMBOO模型借鑒竹子的特性,強調快速成長、韌性、群體發展模式以及對外部環境的快速適應性。本研究主要採用了資源基礎理論(Resource-Based Theory, RBT)和動態能力理論(Dynamic Capabilities Theory, DCT)作為理論框架,並通過次級資料分析、層級分析法與針對行業內的專家訪談,評估台灣生物製藥CDMO產業發展的各項關鍵因素。
本研究探討台灣CDMO藥廠在數位賦能與增加數位韌性方面的發展過程。通過次級資料分析、專家訪談和AHP問卷調查發現,目前多數台灣CDMO公司專注於政策與市場需求,對於組織內外部資源與能力的關注較少。本研究認為,數位賦能與數位韌性是台灣CDMO產業實現跳蛙式增長的契機。數位轉型可以幫助CDMO藥廠強化其能力,通過數位賦能與新增數位韌性,提升其在全球市場中的競爭力。 BAMBOO模型為產業提供了一個具體的發展策略,強調快速成長、韌性和群體發展模式,期望通過這些特性來提升台灣CDMO產業的競爭力和國際影響力。台灣是一個以AI、ICT與代工聞名的國家,我們的產業在智慧製造、數位賦能的柔性生產方面有著既存優勢,使得台灣CDMO產業在數位轉型過程中相對容易。期望台灣能善用此優勢,如同竹子一般,在政府各方面支持的灌溉下,以群體為單位發展,追趕甚至超越其他國家。通過數位賦能與新增數位韌性,台灣的CDMO產業有望成為新一代“護國神山”。 | zh_TW |
dc.description.abstract | This study aims to analyze the current status and future development of Taiwan's CDMO (Contract Development and Manufacturing Organization) industry in biopharmaceuticals, and to construct a model named BAMBOO to metaphorically represent the characteristics and development strategies of Taiwan's biopharmaceutical industry. The BAMBOO model draws inspiration from the characteristics of bamboo, emphasizing rapid growth, resilience, collective development, and quick adaptability to external environments. This study primarily adopts the Resource-Based Theory (RBT) and Dynamic Capabilities Theory (DCT) as the theoretical framework, and evaluates the key factors in the development of Taiwan's biopharmaceutical CDMO industry through secondary data analysis, Analytic Hierarchy Process (AHP), and expert interviews within the industry.
This study explores the process of digital empowerment and enhancing digital resilience in Taiwanese CDMO companies. Through secondary data analysis, expert interviews, and AHP questionnaire surveys, it was found that most Taiwanese CDMO companies currently focus on regulatory and market demands, with less attention to internal and external resources and capabilities. This study suggests that digital empowerment and digital resilience present an opportunity for leapfrog growth in Taiwan's CDMO industry. Digital transformation can help CDMO companies strengthen their capabilities and improve their competitiveness in the global market through digital empowerment and the addition of digital resilience. The BAMBOO model provides a concrete development strategy for the industry, emphasizing rapid growth, resilience, and collective development. It is expected that these characteristics will enhance the competitiveness and international influence of Taiwan's CDMO industry. Taiwan is known for its AI、ICT and OEM industries, and our existing advantages in smart manufacturing and flexible production through digital empowerment make the digital transformation process relatively easier for Taiwan's CDMO industry. It is hoped that Taiwan can leverage these advantages, like bamboo, to develop as a collective unit with the support of the government, catching up with and even surpassing other countries. Through digital empowerment and the enhancement of digital resilience, Taiwan's CDMO industry is poised to become the new " magic mountains that protects the nation." | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-07-23T16:22:26Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2024-07-23T16:22:26Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 目次
致謝 II 摘要 III ABSTRACT V 目次 VII 表次 XI 圖次 XIII 第一章、緒論 1 第一節、研究背景與研究動機 1 1.1.1 研究背景 1 1.1.2 研究動機、 3 第二節、研究問題與目的 4 1.2.1 研究問題與目的 4 第二章、文獻探討 9 第一節、CDMO產業定義、範疇 9 2.1.1 生物製藥與CDMO產業定義與範疇 9 2.1.2 國際CDMO產業概況 10 2.1.3 台灣CDMO產業概況 13 第二節、價值鏈分析 15 2.2.1 生物製藥產業價值鏈 15 2.2.2. CDMO在價值鏈中的角色 16 第三節、當前制度、環境與組織的能力限制 20 2.3.1 資源基礎理論與動態能力理論 20 2.3.2 後進國家發展策略 23 2.3.3 當前台灣目前大分子藥CDMO行業制度分析 25 2.3.4 當前台灣目前大分子藥CDMO行業環境分析 27 2.3.5 當前台灣目前大分子藥CDMO能力分析 28 第四節、Pharma 4.0價值創造 31 2.4.1 生物藥廠進行數位轉型的驅動力 31 2.4.2 Pharma 4.0數位轉型 32 2.4.3 生物藥廠數位成熟度模型 33 2.4.4 數位賦能CDMO 35 第三章、研究方法 38 第一節、研究流程與架構 38 3.1.1 研究架構 38 3.1.2 研究流程 40 第二節 資料來源 42 3.2.1 次級資料來源 42 3.2.2 初級資料來源 42 3.2.2.1 AHP層級分析法專家問卷 42 3.2.2.2 深度訪談法(In-depth Interview) 43 第三節 分析方法 44 3.3.1 次級資料分析 44 3.3.2 AHP初級資料分析 45 第四節、AHP問卷設計 48 3.4.1 研究對象 48 3.4.2 問卷調查取樣 49 3.4.3 問卷設計 49 第四章、研究結果分析與討論 56 第一節 次級資料分析 56 第二節、AHP專家問卷分析 69 4.2.1 受訪者分析 69 4.2.2 數位成熟度變化分析 71 4.2.3 關鍵構面分析 73 4.2.4 關鍵因素分析 76 4.2.5 AHP問卷調查結果分析 84 第三節 專家訪談結果分析 85 第四節、Pharma 4.0與 CDMO數位賦能之探討 91 第五節、台灣CDMO產業未來發產策略 95 第六節 小結-BAMBOO模型 97 第五章、結論與建議 101 第一節 研究結論 101 第二節、研究建議 103 第三節、研究限制 105 參考文獻 106 | - |
dc.language.iso | zh_TW | - |
dc.title | 超越後進追趕:建構BAMBOO架構分析臺灣CDMO廠商的現況與發展韌性 | zh_TW |
dc.title | Beyond Latecomer Catch-up: Constructing the BAMBOO Framework to Analyze the Current Situation and Development Resilience of Taiwanese CDMO Manufacturers | en |
dc.type | Thesis | - |
dc.date.schoolyear | 112-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 陳鴻基;余峻瑜;潘令妍 | zh_TW |
dc.contributor.oralexamcommittee | Houn-Gee Chen;Jiun-Yu Yu;Ling-Yen Pan | en |
dc.subject.keyword | CDMO,Pharma 4.0,數位賦能,BAMBOO,層級分析法, | zh_TW |
dc.subject.keyword | CDMO,Pharma 4.0,Digital Empowerment,BAMBOO,Analytic Hierarchy Process (AHP), | en |
dc.relation.page | 108 | - |
dc.identifier.doi | 10.6342/NTU202401752 | - |
dc.rights.note | 同意授權(全球公開) | - |
dc.date.accepted | 2024-07-16 | - |
dc.contributor.author-college | 進修推廣學院 | - |
dc.contributor.author-dept | 生物科技管理碩士在職學位學程 | - |
顯示於系所單位: | 生物科技管理碩士在職學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-112-2.pdf | 2.02 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。